Form DEFA14A Trinity Capital Inc.
Tweet
Share
E-mailUNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
|
Filed by the Registrant ☒
|
|
|
|
|
|
Filed by a Party other than the Registrant ☐
|
|
|
|
|
|
Check the appropriate box:
|
|
|
|
|
| ☐ |
Preliminary Proxy Statement
|
|
|
|
| ☐ |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
|
|
|
|
| ☐ |
Definitive Proxy Statement
|
|
|
|
| ☒ |
Definitive Additional Materials
|
|
|
|
| ☐ |
Soliciting Material under §240.14a-12
|
|
TRINITY CAPITAL INC.
|
|
(Name of Registrant as Specified In Its Charter)
|
|
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
|
Payment of Filing Fee (Check the appropriate box):
| ☒ |
No fee required.
|
|
|
|
| ☐ |
Fee paid previously with preliminary materials.
|
|
|
|
| ☐ |
Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14(a)-6(i)(1) and 0-11.
|
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trinity Capital Declares Monthly Cash Distribution of $0.17 per Share for the Third Quarter of 2026
- Dimensional Fund Advisors Ltd. : Form 8.3 - GAMMA COMMUNICATIONS PLC - Ordinary Shares
- Organon Canada and Henlius Expand Access to Denosumab Treatments With Launch of BILDYOS® (denosumab injection) and TUZEMTY® (denosumab injection), Biosimilars to PROLIA and XGEVA
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
